K

P

Pictet Alternative Advisors

Crunchbase
Pitchbook
Crunchbase

Deals on record

8

Common Fundraising Type

Equity

F
Fairmat

Carbon composite recycling • Sustainable materials

Slate VC logo
Bpifrance logo
Temasek logo
Singular logo

Fairmat is a French startup that develops carbon composite recycling technology to enable near-infinite reuse of carbon fibers for sustainable materials.

Hybrid B
$55.6M
04/02/2025
Article
A
Antag Therapeutics

Biopharmaceutical • Obesity

Versant Ventures logo
SR One logo
Pictet logo
Novo Holdings logo

Antag Therapeutics is a biopharmaceutical company developing treatments for obesity and cardiometabolic diseases, focusing on injectable therapies like their novel GIPR antagonist, AT-7687.

Series A
$84.1M
12/04/2024
Article
C
Caresyntax

AI-enabled • Surgical software

Symbiotic Capital logo
Relyens Group logo
ProAssurance logo
Plug & Play logo

Caresyntax develops AI-enabled surgical software that enhances surgical outcomes by integrating and analyzing comprehensive data to support real-time and post-surgical decision-making.

Hybrid C
$180M
08/16/2024
Article
C
Caresyntax

AI-enabled • Surgical software

surgical.ai logo
Symbiotic Capital logo
Relyens logo
Pictet Alternative Advisors logo

Caresyntax develops AI-enabled surgical software that enhances surgical outcomes by integrating and analyzing comprehensive data to support real-time and post-surgical decision-making.

Series C
$180M
08/15/2024
Article
R
RefleXion Medical

Therapeutic Oncology • Solid Tumor Cancer Treatment

Venrock logo
TPG logo
T.Rowe Price Associates logo
Square Point Capital logo

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Equity
$105M
11/15/2023
Article
M
Mamaearth

Skincare • Personal Care

White Oak logo
Pictet logo
Norges Bank logo
Matthews logo

Mamaearth is a digital-first skincare and personal care brand that has raised $92 million in an anchor round ahead of its IPO, aiming to secure a total of $204.3 million, and plans to use the funds to support its growth and expansion.

Equity
$92M
10/30/2023
Article
H
Harbinger Health

Biotechnology • Cancer Screening

Flagship Pioneering logo
Pictet logo
Partners Investment logo
M&G logo

Harbinger Health is a biotechnology company that is developing a blood-based cancer screening product, utilizing machine learning and proprietary insights into cancer biology, with the aim to make cancer screening globally accessible, affordable, and reduce false positives.

Series B
$140M
09/28/2023
Article
G
Generate:Biomedicines

Biotherapeutics • Machine Learning in Drug Development

Generate:Biomedicines is a clinical-stage biotherapeutics company that uses a machine-learning-powered generative biology platform to develop new drugs across oncology, immunology, and infectious disease.

Series C
$273M
09/14/2023
Article